Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

NOP receptor antagonism reduces alcohol drinking in male and female rats through mechanisms involving the central amygdala and ventral tegmental area.

Autor: Borruto AM; School of Pharmacy, Pharmacology Unit, University of Camerino, Italy., Fotio Y; School of Pharmacy, Pharmacology Unit, University of Camerino, Italy., Stopponi S; School of Pharmacy, Pharmacology Unit, University of Camerino, Italy., Brunori G; School of Pharmacy, Pharmacology Unit, University of Camerino, Italy.; Department of Biomedical Science, Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida, USA., Petrella M; School of Pharmacy, Pharmacology Unit, University of Camerino, Italy., Caputi FF; Department of Pharmacy and Biotechnology, Alma Mater Studiorum, University of Bologna, Bologna, Italy., Romualdi P; Department of Pharmacy and Biotechnology, Alma Mater Studiorum, University of Bologna, Bologna, Italy., Candeletti S; Department of Pharmacy and Biotechnology, Alma Mater Studiorum, University of Bologna, Bologna, Italy., Narendran R; Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.; Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Rorick-Kehn LM; Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, USA., Ubaldi M; School of Pharmacy, Pharmacology Unit, University of Camerino, Italy., Weiss F; Department of Molecular and Cellular Neuroscience, The Scripps Research Institute, La Jolla, California, USA., Ciccocioppo R; School of Pharmacy, Pharmacology Unit, University of Camerino, Italy.

Publikováno v: British journal of pharmacology [Br J Pharmacol] 2020 Apr; Vol. 177 (7), pp. 1525-1537. Date of Electronic Publication: 2020 Feb 03.

Genetic Deletion of the Nociceptin/Orphanin FQ Receptor in the Rat Confers Resilience to the Development of Drug Addiction.

Autor: Kallupi M; School of Pharmacy, Pharmacology Unit, University of Camerino, Camerino, Italy.; Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, La Jolla, CA, USA., Scuppa G; School of Pharmacy, Pharmacology Unit, University of Camerino, Camerino, Italy., de Guglielmo G; School of Pharmacy, Pharmacology Unit, University of Camerino, Camerino, Italy.; Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, La Jolla, CA, USA., Calò G; Department of Medical Science, Section of Pharmacology and National Institute of Neuroscience, University of Ferrara, Ferrara, Italy., Weiss F; Molecular and Cellular Neuroscience Department, The Scripps Research Institute, La Jolla, CA, USA., Statnick MA; Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN USA., Rorick-Kehn LM; Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN USA., Ciccocioppo R; School of Pharmacy, Pharmacology Unit, University of Camerino, Camerino, Italy.

Publikováno v: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology [Neuropsychopharmacology] 2017 Feb; Vol. 42 (3), pp. 695-706. Date of Electronic Publication: 2016 Aug 26.

The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits.

Autor: Witkin JM; Departments of Neuroscience and Discovery Chemistry, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (J.M.W., J.A.M., D.D.S., X.L., C.O., B.J., K.R., L.M.R.-K.), and Windlesham, Surrey, UK (S.N.M., G.C.) jwitkin@lilly.com., Monn JA; Departments of Neuroscience and Discovery Chemistry, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (J.M.W., J.A.M., D.D.S., X.L., C.O., B.J., K.R., L.M.R.-K.), and Windlesham, Surrey, UK (S.N.M., G.C.)., Schoepp DD; Departments of Neuroscience and Discovery Chemistry, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (J.M.W., J.A.M., D.D.S., X.L., C.O., B.J., K.R., L.M.R.-K.), and Windlesham, Surrey, UK (S.N.M., G.C.)., Li X; Departments of Neuroscience and Discovery Chemistry, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (J.M.W., J.A.M., D.D.S., X.L., C.O., B.J., K.R., L.M.R.-K.), and Windlesham, Surrey, UK (S.N.M., G.C.)., Overshiner C; Departments of Neuroscience and Discovery Chemistry, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (J.M.W., J.A.M., D.D.S., X.L., C.O., B.J., K.R., L.M.R.-K.), and Windlesham, Surrey, UK (S.N.M., G.C.)., Mitchell SN; Departments of Neuroscience and Discovery Chemistry, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (J.M.W., J.A.M., D.D.S., X.L., C.O., B.J., K.R., L.M.R.-K.), and Windlesham, Surrey, UK (S.N.M., G.C.)., Carter G; Departments of Neuroscience and Discovery Chemistry, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (J.M.W., J.A.M., D.D.S., X.L., C.O., B.J., K.R., L.M.R.-K.), and Windlesham, Surrey, UK (S.N.M., G.C.)., Johnson B; Departments of Neuroscience and Discovery Chemistry, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (J.M.W., J.A.M., D.D.S., X.L., C.O., B.J., K.R., L.M.R.-K.), and Windlesham, Surrey, UK (S.N.M., G.C.)., Rasmussen K; Departments of Neuroscience and Discovery Chemistry, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (J.M.W., J.A.M., D.D.S., X.L., C.O., B.J., K.R., L.M.R.-K.), and Windlesham, Surrey, UK (S.N.M., G.C.)., Rorick-Kehn LM; Departments of Neuroscience and Discovery Chemistry, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (J.M.W., J.A.M., D.D.S., X.L., C.O., B.J., K.R., L.M.R.-K.), and Windlesham, Surrey, UK (S.N.M., G.C.).

Publikováno v: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2016 Jul; Vol. 358 (1), pp. 71-82. Date of Electronic Publication: 2016 May 12.

Determining pharmacological selectivity of the kappa opioid receptor antagonist LY2456302 using pupillometry as a translational biomarker in rat and human.

Autor: Rorick-Kehn LM; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana (Drs Rorick-Kehn, Witcher, Lowe, Gonzales, Bell, Hard, Need, J. McKinzie, Statnick, Suico, D. McKinzie, Tauscher-Wisniewski, Mitch, and Wong); inVentiv Health Clinical, Ann Arbor, Michigan (Dr Weller); Covance Clinical Research Unit, Inc., Evansville, Indiana (Dr Stoltz). rorickkehnlm@lilly.com., Witcher JW; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana (Drs Rorick-Kehn, Witcher, Lowe, Gonzales, Bell, Hard, Need, J. McKinzie, Statnick, Suico, D. McKinzie, Tauscher-Wisniewski, Mitch, and Wong); inVentiv Health Clinical, Ann Arbor, Michigan (Dr Weller); Covance Clinical Research Unit, Inc., Evansville, Indiana (Dr Stoltz)., Lowe SL; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana (Drs Rorick-Kehn, Witcher, Lowe, Gonzales, Bell, Hard, Need, J. McKinzie, Statnick, Suico, D. McKinzie, Tauscher-Wisniewski, Mitch, and Wong); inVentiv Health Clinical, Ann Arbor, Michigan (Dr Weller); Covance Clinical Research Unit, Inc., Evansville, Indiana (Dr Stoltz)., Gonzales CR; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana (Drs Rorick-Kehn, Witcher, Lowe, Gonzales, Bell, Hard, Need, J. McKinzie, Statnick, Suico, D. McKinzie, Tauscher-Wisniewski, Mitch, and Wong); inVentiv Health Clinical, Ann Arbor, Michigan (Dr Weller); Covance Clinical Research Unit, Inc., Evansville, Indiana (Dr Stoltz)., Weller MA; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana (Drs Rorick-Kehn, Witcher, Lowe, Gonzales, Bell, Hard, Need, J. McKinzie, Statnick, Suico, D. McKinzie, Tauscher-Wisniewski, Mitch, and Wong); inVentiv Health Clinical, Ann Arbor, Michigan (Dr Weller); Covance Clinical Research Unit, Inc., Evansville, Indiana (Dr Stoltz)., Bell RL; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana (Drs Rorick-Kehn, Witcher, Lowe, Gonzales, Bell, Hard, Need, J. McKinzie, Statnick, Suico, D. McKinzie, Tauscher-Wisniewski, Mitch, and Wong); inVentiv Health Clinical, Ann Arbor, Michigan (Dr Weller); Covance Clinical Research Unit, Inc., Evansville, Indiana (Dr Stoltz)., Hart JC; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana (Drs Rorick-Kehn, Witcher, Lowe, Gonzales, Bell, Hard, Need, J. McKinzie, Statnick, Suico, D. McKinzie, Tauscher-Wisniewski, Mitch, and Wong); inVentiv Health Clinical, Ann Arbor, Michigan (Dr Weller); Covance Clinical Research Unit, Inc., Evansville, Indiana (Dr Stoltz)., Need AB; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana (Drs Rorick-Kehn, Witcher, Lowe, Gonzales, Bell, Hard, Need, J. McKinzie, Statnick, Suico, D. McKinzie, Tauscher-Wisniewski, Mitch, and Wong); inVentiv Health Clinical, Ann Arbor, Michigan (Dr Weller); Covance Clinical Research Unit, Inc., Evansville, Indiana (Dr Stoltz)., McKinzie JH; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana (Drs Rorick-Kehn, Witcher, Lowe, Gonzales, Bell, Hard, Need, J. McKinzie, Statnick, Suico, D. McKinzie, Tauscher-Wisniewski, Mitch, and Wong); inVentiv Health Clinical, Ann Arbor, Michigan (Dr Weller); Covance Clinical Research Unit, Inc., Evansville, Indiana (Dr Stoltz)., Statnick MA; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana (Drs Rorick-Kehn, Witcher, Lowe, Gonzales, Bell, Hard, Need, J. McKinzie, Statnick, Suico, D. McKinzie, Tauscher-Wisniewski, Mitch, and Wong); inVentiv Health Clinical, Ann Arbor, Michigan (Dr Weller); Covance Clinical Research Unit, Inc., Evansville, Indiana (Dr Stoltz)., Suico JG; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana (Drs Rorick-Kehn, Witcher, Lowe, Gonzales, Bell, Hard, Need, J. McKinzie, Statnick, Suico, D. McKinzie, Tauscher-Wisniewski, Mitch, and Wong); inVentiv Health Clinical, Ann Arbor, Michigan (Dr Weller); Covance Clinical Research Unit, Inc., Evansville, Indiana (Dr Stoltz)., McKinzie DL; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana (Drs Rorick-Kehn, Witcher, Lowe, Gonzales, Bell, Hard, Need, J. McKinzie, Statnick, Suico, D. McKinzie, Tauscher-Wisniewski, Mitch, and Wong); inVentiv Health Clinical, Ann Arbor, Michigan (Dr Weller); Covance Clinical Research Unit, Inc., Evansville, Indiana (Dr Stoltz)., Tauscher-Wisniewski S; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana (Drs Rorick-Kehn, Witcher, Lowe, Gonzales, Bell, Hard, Need, J. McKinzie, Statnick, Suico, D. McKinzie, Tauscher-Wisniewski, Mitch, and Wong); inVentiv Health Clinical, Ann Arbor, Michigan (Dr Weller); Covance Clinical Research Unit, Inc., Evansville, Indiana (Dr Stoltz)., Mitch CH; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana (Drs Rorick-Kehn, Witcher, Lowe, Gonzales, Bell, Hard, Need, J. McKinzie, Statnick, Suico, D. McKinzie, Tauscher-Wisniewski, Mitch, and Wong); inVentiv Health Clinical, Ann Arbor, Michigan (Dr Weller); Covance Clinical Research Unit, Inc., Evansville, Indiana (Dr Stoltz)., Stoltz RR; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana (Drs Rorick-Kehn, Witcher, Lowe, Gonzales, Bell, Hard, Need, J. McKinzie, Statnick, Suico, D. McKinzie, Tauscher-Wisniewski, Mitch, and Wong); inVentiv Health Clinical, Ann Arbor, Michigan (Dr Weller); Covance Clinical Research Unit, Inc., Evansville, Indiana (Dr Stoltz)., Wong CJ; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana (Drs Rorick-Kehn, Witcher, Lowe, Gonzales, Bell, Hard, Need, J. McKinzie, Statnick, Suico, D. McKinzie, Tauscher-Wisniewski, Mitch, and Wong); inVentiv Health Clinical, Ann Arbor, Michigan (Dr Weller); Covance Clinical Research Unit, Inc., Evansville, Indiana (Dr Stoltz).

Publikováno v: The international journal of neuropsychopharmacology [Int J Neuropsychopharmacol] 2014 Oct 31; Vol. 18 (2). Date of Electronic Publication: 2014 Oct 31.